Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 5/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | BCL2 | P10415 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | APAF1 | O14727 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | TDP2 | O95551 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29365382 | 1.00 | STAT3 (0.69) | STAT3ALDH1A1KMT2AMEN1CDC25B | |
| SCHEMBL19669614 | 0.87 | STAT3 (0.59) | STAT3ALDH1A1KMT2AMEN1CDC25B | |
| SCHEMBL18030270 | 0.86 | STAT3 (0.58) | STAT3ALDH1A1KMT2AMEN1CDC25B | |
| SCHEMBL30139971 | 0.84 | STAT3 (0.56) | STAT3ALDH1A1KMT2AMEN1CDC25B | |
| SCHEMBL22325627 | 0.84 | ALDH1A1 (0.56) | STAT3ALDH1A1KMT2AMEN1CDC25B | |
| SCHEMBL12494854 | 0.83 | STAT3 (0.55) | STAT3ALDH1A1KMT2AMEN1CDC25B | |
| SCHEMBL10037431 | 0.82 | STAT3 (1.00) | STAT3ALDH1A1KMT2AMEN1CDC25B | |
| SCHEMBL866692 | 0.82 | STAT3 (1.00) | STAT3ALDH1A1KMT2AMEN1CDC25B | |
| SCHEMBL2801404 | 0.82 | STAT3 (1.00) | STAT3ALDH1A1KMT2AMEN1CDC25B | |
| SCHEMBL3715764 | 0.82 | STAT3 (0.54) | STAT3ALDH1A1KMT2AMEN1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3067054-B1 | NOVEL COMPOSITIONS AND METHODS FOR CANCER TREATMENT | BOSTON BIOMEDICAL INC (US) | 2020-12-30 | — | — | EP | claimed |
| EP-3050566-B1 | A NOVEL GROUP OF STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL PATHWAY INHIBITORS | BOSTON BIOMEDICAL INC (US) | 2018-11-28 | — | — | EP | claimed |
| US-20180250261-A1 | METHOD FOR TREATING CANCER WITH A STAT3 PATHWAY INHIBITOR AND KINASE INHIBITOR | BOSTON BIOMEDICAL, INC. (US) | 2018-09-06 | — | — | US | claimed |
| US-20180140572-A1 | COMPOSITIONS COMPRISING A CANCER STEMNESS INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT FOR USE IN TREATING CANCER | BOSTON BIOMEDICAL, INC. | 2018-05-24 | — | — | US | claimed |
| US-20180030021-A1 | NOVEL COMPOSITIONS AND METHODS FOR CANCER TREATMENT | BOSTON BIOMEDICAL, INC. (US) | 2018-02-01 | — | — | US | claimed |
| WO-2018005444-A2 | METHODS FOR TREATING CANCER | BOSTON BIOMEDICAL, INC. (US) | 2018-01-04 | — | — | WO | claimed |
| EP-3067054-A1 | NOVEL COMPOSITIONS AND METHODS FOR CANCER TREATMENT | Boston Biomedical, Inc. (US) | 2016-09-14 | — | — | EP | claimed |
| EP-3058941-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | Boston Biomedical, Inc. (US) | 2016-08-24 | — | — | EP | claimed |
| EP-3050566-A2 | A NOVEL GROUP OF STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL PATHWAY INHIBITORS | Boston Biomedical, Inc. (US) | 2016-08-03 | — | — | EP | claimed |
| EP-2200431-B1 | NOVEL COMPOSITIONS AND METHODS FOR CANCER TREATMENT | BOSTON BIOMEDICAL INC (US) | 2016-07-20 | — | — | EP | claimed |
| US-20120252763-A1 | NOVEL GROUP OF STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL PATHWAY INHIBITORS | BOSTON BIOMEDICAL, INC. (US) | 2012-10-04 | — | — | US | claimed |
| US-20110112180-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL, INC. (US) | 2011-05-12 | — | — | US | claimed |
| US-20100310503-A1 | NOVEL COMPOSITIONS AND METHODS FOR CANCER TREATMENT | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. | 2010-12-09 | — | — | US | claimed |
| EP-2200431-A1 | NOVEL COMPOSITIONS AND METHODS FOR CANCER TREATMENT | Boston Biomedical, Inc. (US) | 2010-06-30 | — | — | EP | claimed |
| EP-2194987-A2 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | Boston Biomedical, Inc. (US) | 2010-06-16 | — | — | EP | claimed |
| EP-2190429-A1 | A NOVEL GROUP OF STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL PATHWAY INHIBITORS | Boston Biomedical, Inc. (US) | 2010-06-02 | — | — | EP | claimed |
| WO-2009036101-A1 | NOVEL COMPOSITIONS AND METHODS FOR CANCER TREATMENT | BOSTON BIOMEDICAL, INC. (US) | 2009-03-19 | — | — | WO | claimed |
| WO-2009036099-A1 | A NOVEL GROUP OF STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL PATHWAY INHIBITORS | BOSTON BIOMEDICAL, INC. (US) | 2009-03-19 | — | — | WO | claimed |
| WO-2009036059-A2 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL, INC. (US) | 2009-03-19 | — | — | WO | claimed |
| EP-1134216-B1 | ANTI-DRUG RESISTANT STRAIN AGENTS AND ANTICHLAMYDIA AGENTS | JAPAN SCIENCE & TECH CORP (JP) | 2004-05-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112180-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | STAT3, STAT1, STAT5B | STAT3 1/4885ALDH1A1 630/4885KMT2A 1673/4885 |
| US-20180250261-A1 | METHOD FOR TREATING CANCER WITH A STAT3 PATHWAY INHIBITOR AND KINASE INHIBITOR | STAT3, JAK2, STAT1 | STAT3 1/4885ALDH1A1 1073/4885KMT2A 677/4885 |
| US-20120252763-A1 | NOVEL GROUP OF STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL PATHWAY INHIBITORS | STAT3, JAK2, STAT5B | STAT3 1/4885ALDH1A1 810/4885KMT2A 2177/4885 |
| US-20180140572-A1 | COMPOSITIONS COMPRISING A CANCER STEMNESS INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT FOR USE IN TREATING CANCER | CD44, CD47, BMI1 | STAT3 4/4885ALDH1A1 58/4885KMT2A 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.